Investigations at the time showed no evidence of an allergic disorder. However, serum mast cell tryptase levels were periodically elevated, ranging from 10 mg/mL to 20 ng/mL between attacks, but increasing to >100 ng/mL following episodes of anaphylaxis. Subsequent investigations to exclude a clonal mast cell disorder were performed in another center. This included a complete bone marrow study to assess the number of mast cells and typical histological lesions of systemic mastocytosis, such as multifocal dense, sharply demarcated mast cell infiltrates [5] . Furthermore, bone marrow aspirate was examined for the number of mast cells and their morphological features, and immunophenotyping studies were performed to assess expression of CD2 and CD25, which are typically found on mast cells from patients with systemic mastocytosis [5] . Lastly, cKIT mutation analysis yielded negative results; however, we do not know if this was performed from purified mast cells, as currently recommended [6] . Altogether, these investigations showed no evidence of clonal mast cell proliferation.
Nonclonal mast cell activation syndrome (ncMCAS) is a disorder characterized by episodic mast cell degranulation and the effect of this process on target organ systems [1] . To meet the diagnostic criteria for ncMCAS, the episodes must involve 2 or more organ systems in the absence of a primary or secondary cause of mast cell activation (MCA), including systemic mastocytosis. Furthermore, there must be a recorded rise in urine or serum levels of mast cell degranulation markers, and the condition must be responsive to antimediator therapy such as histamine 1 and 2 receptor antagonists, leukotriene antagonists, and mast cell stabilizers [1] . A proportion of patients with ncMCAS also have concomitant postural orthostatic tachycardia syndrome (POTS) [2] . POTS is a heterogenous form of orthostatic intolerance characterized by an increase in the heart rate of at least 30 bpm within 10 minutes of assuming an upright posture. POTS commonly presents with cardiac symptoms (eg, palpitations, lightheadedness, and dyspnea) and noncardiac symptoms (eg, headache, exercise intolerance, fatigue) [3] . The link between these 2 clinical entities is not entirely clear, although it has been suggested that the vasodilator effect of MCA-related mediators such as histamine, norepinephrine, and neuropeptide Y (NPY) results in increased sympathetic activity, which in turn leads to orthostatic tachycardia [2] . In recent years, a handful of patients with recalcitrant ncMCAS were successfully treated with omalizumab, the monoclonal antibody to IgE [4] .
Here, we present a patient with coexisting ncMCAS and POTS, whose ncMCAS-related symptoms responded fully to omalizumab but who remains extremely symptomatic with POTS.
This 21-year-old British male initially presented at the age of 10 years with recurrent episodes of unexplained anaphylaxis occurring on a 2-weekly to 2-monthly basis. There were no obvious triggers to these episodes. In addition to anaphylaxis, he reported having more persistent symptoms, including almost daily flushing, profuse sweating, hives, and occasional wheeziness. In his late teens he developed episodic diarrhea, erythromelalgia, severe dizziness associated with hypotension, and tachycardia and experienced loss of consciousness.
Subcutaneous omalizumab was initially commenced at a dose of 300 mg every 4 weeks, but the frequency of injections later increased to 3-weekly owing to mild breakthrough MCAS symptoms. Since commencing omalizumab 2 years ago, the patient has had no further episodes of urticaria, anaphylaxis, or loss of consciousness. However, he remains severely affected by POTS-associated symptoms including diarrhea, excessive sweating, and erythromelalgia.
The co-occurrence of MCAS and POTS in some patients suggests that both clinical entities might share a common pathological pathway. Indeed, mast cells might contain chemical mediators other than histamine, with physiological effects that could reproduce POTS-related symptoms [2] . It might therefore be expected that agents preventing mast cell degranulation, such as omalizumab, could be effective for both disorders. The effect of omalizumab on non-IgE-mediated MCA is now believed to be exerted via 2 mechanisms: first, binding to specific IgE molecules that recognize autoantigens and block their function [8] ; and second, down-regulation of the mast cell high-affinity IgE receptor, FCεRI [4] . Failure of omalizumab in this case to alleviate POTS symptoms might be due to a differential mast cell activation pathway not disrupted by the anti-IgE drug. Differential mast cell activation without degranulation has previously been observed in the context of various inflammatory processes, and may be triggered by numerous mediators such as cytokines, hormones, and growth factors, as well as microbial antigens [9] .
Another feature common to these conditions is their likely autoimmune etiology. Recent studies have pointed to an autoimmune etiology of chronic spontaneous urticaria through the action of IgE isotype antibodies to thyroid peroxidase which cross-react with the high-affinity mast cell IgE receptor FCεRI [10] . A similar mechanism has been thought to be responsible in ncMCAS. In articles describing the association of autoimmunity and POTS, the causative autoantibodies were of the IgG isotype [11] . The initial failure of omalizumab to neutralize potential POTScausing IgE antibodies could therefore be attributed to its specificity towards the wrong immunoglobulin isotype. The subsequent failure of immunomodulatory intravenous immunoglobulin and plasmapheresis in eliciting clinical improvement, however, could be attributed to their inability to accurately target the casuative antibodies, or to absence of the autoantibodies themselves. Case reports describing treatment of POTS symptoms with plasmapheresis [12] or high-dose immunoglobulin [13] involved proven anti-NMDA receptor autoantibodies, which were not found in this patient's case.
A positive therapeutic response to a targeted treatment can occasionally be extremely helpful to delineate an underlying pathological mechanism. The introduction of omalizumab for treatment of chronic spontaneous urticaria has certainly helped to improve our understanding of this condition. However, in this case, the response to omalizumab was only partial, suggesting that 2 clinical entities, ncMCAS and POTS, while occurring concurrently and in the same patient, might not be caused by entirely identical pathological processes. Nevertheless, symptoms of nsMCAS and POTS can be triggered by mast cell mediators. In addition, both conditions often have an autoimmune basis. Therefore, it is likely that a common pathological process, at least in part and yet to be fully delineated, underlies these 2 conditions. Polyvinylpyrrolidone (PVP) is a polymer derived from the monomer N-vinylpyrrolidone, an organic compound consisting of a 5-membered lactam linked to a vinyl group. It is widely used in medical products as an excipient, especially in tablet formulations, and in ophthalmic solutions as a lubricant. When linked to iodine, it is called povidone-iodine, which is used as an antiseptic agent.
Even though PVP has been considered safe to date, cases of adverse reactions have been reported. While skin reactions to PVP from cutaneous exposure, such as contact dermatitis, are frequent, only a few cases of anaphylaxis from various administration routes have been described in the literature [1] [2] [3] [4] [5] .
Few cases of anaphylaxis to eye drops have been reported; some involved reactions to the active ingredient [6, 7] and only 1 to the preservative, benzalkonium chloride [8] .
We report the first case of anaphylaxis to PVP as an excipient in an ophthalmic preparation.
A 15-year-old girl was referred to the Allergy Unit of the Anna Meyer Children's Hospital, Florence, Italy because of suspected anaphylaxis to eye drops.
The only relevant information in her clinical history was a previous reaction following exposure to a hairspray at the hairdresser's some months earlier. At that time, the patient experienced cutaneous itching of the scalp, tearing, and cough. The symptoms cleared up spontaneously in a few minutes.
Two months before our evaluation, she had conjunctivitis and was treated with topical tobramycin and dexamethasone eye drops, with no reaction. A month and half later, owing to recurrent conjunctivitis, the ophthalmologist prescribed another type of corticosteroid eye drops, which contained loteprednol. Immediately after the administration of one drop in both eyes, she developed anaphylaxis (periorbital swelling, angioedema of the tongue and lips, dyspnea with a sensation of nasal obstruction, and throat constriction). At the emergency department, she was given epinephrine, antihistamines, and oral corticosteroids, and her symptoms resolved progressively. A blood analysis during the episode revealed total IgE of 3850 kU/L (normal range, 0-100 kU/L).
Two weeks after being discharged, the patient was admitted to our Allergy Unit. Prick-by-prick testing with the culprit eye drops containing loteprednol 0.5% yielded a positive result after 10 minutes (Table) . Histamine (ALK-Abelló; 10 mg/mL)
